ストックスクリーナーアプリを入手
1.30
46.40%
0.412
アフターアワーズ：
1.28
-0.02
-1.54%
前日終値:
$0.888
開ける：
$0.9374
24時間の取引高:
4.24M
Relative Volume:
9.96
時価総額：
$71.55M
収益：
-
当期純損益:
$-131.52M
株価収益率:
-0.5991
EPS:
-2.17
ネットキャッシュフロー:
$-107.56M
1週間 パフォーマンス:
+62.50%
1か月 パフォーマンス:
+35.18%
6か月 パフォーマンス:
-64.91%
1年 パフォーマンス:
-67.25%
1日の値動き範囲:
$0.9374
$1.45
1週間の範囲:
$0.7966
$1.45
52週間の値動き範囲:
$0.7966
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
PRLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.30 | 71.55M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Krishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in Stock - MarketBeat
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com India
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com Canada
Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MyChesCo
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo
Prelude Therapeutics presents first interim data from trial of PRT2527 - Yahoo Finance
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Position Increased by Walleye Capital LLC - Defense World
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 - The Bakersfield Californian
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - Yahoo Finance
Sirus Therapeutics announces positive signals from Phase I siRNA trial - Yahoo Finance
PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges - Investing.com Nigeria
November 2024's Top Picks: Penny Stocks On US Exchanges - Simply Wall St
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Yahoo Finance
Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health - TipRanks
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism - MyChesCo
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Yahoo Finance
PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com Australia
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com
Tectonic Therapeutic Inc. Reports Q3 2024 Results - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MyChesCo
Prelude Therapeutics (NASDAQ:PRLD) Given "Buy" Rating at HC Wainwright - MarketBeat
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia
Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World
PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MyChesCo
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa
Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
Prelude Therapeutics Inc (PRLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Dec 18 '24 |
Buy |
0.93 |
100,000 |
93,210 |
1,167,275 |
| Vaddi Krishna | CEO |
Dec 19 '24 |
Buy |
0.89 |
6,888 |
6,116 |
127,553 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):